COVID-19 AND MUCORMYCOSIS: A SHORT REPORT FROM INDIA

Simple item page
dc.contributor.authorFatima, Gen_US
dc.contributor.authorParvez, Sen_US
dc.contributor.authorRaza, AMen_US
dc.contributor.authorFedacko, Jen_US
dc.contributor.authorHadi, NR.en_US
dc.date.accessioned2023-07-21T11:31:09Z
dc.date.available2023-07-21T11:31:09Z
dc.date.issued2021-12
dc.description.abstractMany complications and symptoms were documented on COVID-19 patients in the second-phase of the COVID-19 outbreak in India. Patients with COVID-19 are already of increased risk of pulmonary embolism (PE), acute cardiac injury (ACI), arrhythmias, and a variety of additional consequences such as altered mental status and proptosis. Mucormycosis, a fungal infection produced by a type of moulds known as mucormycetes, was discovered in a COVID-19 patient. It is a very rare and serious fungal infection (Black Fungus). Mucormycosis, one of the most rapidly spreading infections in COVID-19 patients, has been recorded in 11,717 cases in India. Molds dwell in the environment and primarily affect people who have a weak immune system. Inhaling pathogenic organisms from the air usually causes it to harm the sinuses and lungs. COVID-19 individuals have immunosuppressive with significant drop in CD4+T and CD8+T cells, in addition to alveoli damage and severe pulmonary inflammation. As a result, severely ill-patients, particularly those sent in the intensive-care-unit (ICU) and requiring mechanical ventilation, or those with extended hospital stays 40 to 50 days were more susceptible to mucormycosis. Further, it is crucial to find out that COVID-19 patients especially the ones who are severely ill resulting in weaker immune system can further develop a fungal infection during the middle and or latter stages of COVID-19.en_US
dc.identifier.affiliationsDepartment of Biotechnologyen_US
dc.identifier.affiliationsDepartment of Dentistryen_US
dc.identifier.affiliationsDepartment of Cardiologyen_US
dc.identifier.affiliationsDepartment of Pharmacology and Therapeuticsen_US
dc.identifier.affiliationsEra's Lucknow Medical College & Hospital, Era University, Sarfarazganj Lucknow, U.P., India-22600 Career Institute of Medical and Dental Sciences, U.P., India.en_US
dc.identifier.affiliationsPavol Jozef Safarik University, Kosice, Slovakiaen_US
dc.identifier.affiliationsFaculty of Medicine, University of Kufa, Iranen_US
dc.identifier.citationFatima G, Parvez S, Raza AM, Fedacko J, Hadi NR. COVID-19 AND MUCORMYCOSIS: A SHORT REPORT FROM INDIA. Era's Journal of Medical Research. 2021 Dec; 8(2): 204-208en_US
dc.identifier.issn2394-5222
dc.identifier.issn2348-9839
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/220355
dc.languageenen_US
dc.publisherEra's Lucknow Medical College & Hospital, Lucknowen_US
dc.relation.issuenumber2en_US
dc.relation.volume8en_US
dc.source.urihttps://doi.org/10.24041/ejmr2021.38en_US
dc.subjectMucormycosisen_US
dc.subjectCOVID-19en_US
dc.subjectInfectionen_US
dc.subjectIndia.en_US
dc.titleCOVID-19 AND MUCORMYCOSIS: A SHORT REPORT FROM INDIAen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EJMR2021v8n2p204.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format
Download
Collections
Era's Journal of Medical Research